However, meta-analyses of clinical trials has revealed a reduction of 10% in the incidence of both new and recurrent myocardial infarctions with GLP-1RAs [8]
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the body's own GLP-1 hormone
Relative risk compares the likelihood between groups (e.g., twice as likely), while absolute risk reflects the actual chance of an event occurring
Appetite hormones such as ghrelin and leptin influence these signals, and GLP-1 medications may help by improving satiety and dampening reward-driven cues
Aside from clinically indicated reasons such as managing AEs or pausing/de-escalation for excessive weight loss, there is consensus by the authors that GBT should not be discontinued due to ongoing health benefits
While there is no single required diet, these medications work most effectively when paired with a balanced, nutrient-dense eating plan